Trial Profile
Cell Therapy for Craniofacial Bone Defects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixmyelocel-T (Primary)
- Indications Alveolar bone loss
- Focus Therapeutic Use
- 16 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2016, according to ClinicalTrials.gov record.
- 19 May 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015, according to ClinicalTrials.gov record.